Results 21 to 30 of about 5,707 (185)

Late presentation of acromegaly in medically controlled prolactinoma patients

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2016
Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova   +6 more
doaj   +1 more source

PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas

open access: yesFrontiers in Endocrinology, 2022
BackgroundProlactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients.
Kejing Zhu   +10 more
doaj   +1 more source

Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia

open access: yesIndian Journal of Endocrinology and Metabolism, 2017
Background and Objective: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology.
Bindu Kulshreshtha   +6 more
doaj   +1 more source

Giant Prolactinomas [PDF]

open access: yesNeuroendocrinology, 2018
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary. Microprolactinomas (diameter <10 mm) are frequently diagnosed in women, whereas macroprolactinomas (maximum diameter ≥10 mm) are generally seen in men. Most macroprolactinomas measure between 10 and 40 mm.
openaire   +2 more sources

Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1

open access: yesFrontiers in Endocrinology, 2019
Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C. B. Dantas   +6 more
doaj   +1 more source

Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

open access: yesMedicine Science, 2015
It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity.
Mazhar Muslum Tuna   +5 more
doaj   +1 more source

Prolactinoma in a Dog [PDF]

open access: yesVeterinary Pathology, 2017
A 12-year-old male Yorkshire Terrier was presented because of decreased appetite. Physical examination revealed mammary gland swelling and galactorrhea. Contrast-enhanced computed tomographic scanning of the skull indicated an enlarged pituitary gland, compatible with a pituitary tumor. The serum prolactin concentration was markedly elevated.
Cosio, Cristina   +6 more
openaire   +5 more sources

Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia

open access: yesIatreia, 2016
Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto   +3 more
doaj   +1 more source

ACTH suppression and adverse effects of cabergoline in horses with pituitary pars intermedia dysfunction

open access: yesEquine Veterinary Education, EarlyView.
Summary Background The diagnosis and management of pituitary pars intermedia dysfunction (PPID) in horses includes evaluating abnormal plasma concentrations of adrenocorticotrophic hormone (ACTH). Treatment commonly includes the oral dopamine agonist pergolide mesylate, which suppresses the pathologic overproduction of ACTH.
A. Bracken   +5 more
wiley   +1 more source

Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway

open access: yesFrontiers in Pharmacology
ObjectivesThis investigation sought to explore the inhibitory impact of wogonin on prolactinoma and elucidate its underlying mechanisms through network pharmacology, molecular docking (MD), and molecular biology experiments.MethodsTarget identification ...
Zhiyong Du   +29 more
doaj   +1 more source

Home - About - Disclaimer - Privacy